Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
December 06, 2018 07:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass. and SAN CARLOS, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics,...
Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe
November 16, 2018 08:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics (Nasdaq: NTGN) has been named one of the top places to work in Massachusetts by The Boston Globe, an honor awarded based on...
Neon Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
November 12, 2018 16:15 ET
|
Neon Therapeutics, Inc.
Data presented at ESMO and SITC underscore continued clinical progress across platform and pipeline CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a...
Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
November 09, 2018 08:00 ET
|
Neon Therapeutics, Inc.
– Management Hosting Webcast of Key Opinion Leader Discussion Today at 6:00 p.m. ET – CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage...
Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors
November 07, 2018 16:48 ET
|
Neon Therapeutics, Inc.
Seasoned executive brings more than 20 years of biopharmaceutical industry experience CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage...
Neon Therapeutics to Host Investor Event at Society for Immunotherapy of Cancer 33rd Annual Meeting
November 01, 2018 16:15 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it...
Neon Therapeutics Presents Data from Ongoing Phase 1b NT-001 Clinical Trial at European Society for Medical Oncology 2018 Congress
October 22, 2018 06:00 ET
|
Neon Therapeutics, Inc.
Management to Host Conference Call and Webcast Today at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology...
Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
October 18, 2018 16:20 ET
|
Neon Therapeutics, Inc.; Natera, Inc.
Combines Neon’s Personal Neoantigen Vaccine and Signatera (RUO) Circulating Tumor DNA Biomarker in Metastatic Non-Small Cell Lung Cancer Trial SAN CARLOS, Calif. and CAMBRIDGE, Mass., Oct. 18, 2018 ...
Neon Therapeutics to Present Data from Ongoing Phase 1b NT-001 Clinical Trial at the European Society for Medical Oncology 2018 Congress
October 03, 2018 07:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
Neon Therapeutics to Present at the Society for Immunotherapy of Cancer 33rd Annual Meeting
October 01, 2018 17:22 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced...